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Abstract 
Whilst mitotic rat embryonic cardiomyoblast-derived H9c2 cells have been widely used 
as a model system to study the protective mechanisms associated with flavonoids, they 
are not fully differentiated cardiac cells. Hence the aim of this study was to investigate 
the cardioprotective and cardiotoxic actions of quercetin and two of its major in vivo 
metabolites, quercetin 3-glucuronide and 3’-O-methyl quercetin, using differentiated H9c2 
cells. The differentiated cardiomyocyte-like phenotype was confirmed by monitoring 
expression of cardiac troponin 1 following 7 days of culture in reduced serum medium 
containing 10 nM all-trans retinoic acid. Quercetin-induced cardiotoxicity was assessed by 
monitoring MTT reduction, LDH release, caspase 3 activity and reactive oxygen species 
production following prolonged flavonoid exposure (72 h).  Cardiotoxicity was observed 
with quercetin and 3’-O-methyl quercetin but not quercetin 3-glucuronide. 
Cardioprotection was assessed by pre-treating differentiated H9c2 cells with quercetin or its 
metabolites for 24 h prior to 2 h exposure to 600 µM H2O2, after which oxidative stress-
induced cell damage was assessed by measuring MTT reduction and LDH release. 
Cardioprotection was observed with quercetin and 3’-O-methyl quercetin but not with 
quercetin 3-glucuronide. Quercetin attenuated H2O2-induced activation of ERK1/2, PKB, 
p38 MAPK and JNK but inhibitors of these kinases did not modulate quercetin-induced 
protection or H2O2-induced cell death. In summary, quercetin triggers cardioprotection 
against oxidative stress–induced cell death and cardiotoxicity following prolonged exposure. 
Further studies are required to investigate the complex interplay between the numerous 
signalling pathways that are modulated by quercetin and which may contribute to the 
cardioprotective and cardiotoxic effects of this important flavonoid.       
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Introduction 
Flavonoids are a large group of compounds (4000) that occur naturally in fruits, 
vegetables, nuts, seeds, flowers and other plant matter and as such they are an integral 
part of the human diet [1]. They all share a common three-ring structure but are sub-
divided into flavonols, flavons, flavanols and flavanons according to their substituents 
[2]. Epidemiological studies indicate that diets rich in flavonoids are associated with 
reduced incidences of several chronic diseases including cardiovascular disease, asthma, 
type II diabetes and certain types of cancer [3]. The cardioprotective properties of 
flavonoids are multi-faceted involving anti-oxidant, anti-hypercholesterolemia, anti-
inflammatory, and inhibition of platelet aggregation effects [3]. The anti-oxidant 
property of flavonoids was thought, until relatively recently, to underlie the majority of 
their protective cellular effects. However, it is becoming increasingly apparent that 
flavonoids also influence cellular function by modulating the activity of many enzymes 
including the inhibition of protein kinases and lipid kinases [1,4].  
   The inhibitory effect of flavonoids on protein kinase activity is primarily due to their 
ability to function as competitive inhibitors of the ATP-binding domain located in the 
active site of these enzymes [1,4]. Protein kinases directly inhibited by flavonoids 
include protein kinase C (PKC), myosin-light chain kinase (MLCK), and MEK1 [1,4]. MEK1 
is an up-stream kinase responsible for the activation of extracellular signal-regulated 
kinase 1/2 (ERK1/2), a member of the mitogen-activated protein kinase (MAPK) family 
of protein kinases [5]. This family also includes p38 MAPK and JNK signalling pathways, 
both of which are targets for modulation by flavonoids [6-8]. It is also notable that 
flavonoids such as quercetin also inhibit (via competitive inhibition of the ATP-binding 
site) the lipid kinase PI-3K [9], which plays a prominent role in the activation of protein 
kinase B (PKB; also known as Akt).  
   The MEK/ERK1/2 and the PI-3K/PKB pathways are important signalling pathways 
which mediate cell survival and cardioprotection against ischaemia/reperfusion injury 
4 
 
[10,11]. In contrast, p38 MAPK and JNK cascades are typically associated with 
inflammation and cell death; however there is also evidence that they mediate 
cardioprotection [11]. Hence the cardioprotective effects of flavonoids may relate to their 
ability to modulate MAPK and PI-3K/PKB signalling cascades. Indeed, recent studies have 
shown that grape seed proanthocyanidin extract protects cardiomyocytes from 
ischaemia/reperfusion injury via PKB activation  [12]. Similarly, quercetin (the most 
abundant dietary flavonoid) protected H9c2 cardiomyoblasts from H2O2-induced cell 
death via enhancement of ERK1/2 and PI-3K/PKB signalling [13]. In contrast, 
isorhamnetin (a flavonol isolated from sea buckthorn) prevented H2O2-induced activation 
of apoptosis in H9c2 cells through ERK1/2 inactivation [14]. 
   It is notable that rat embryonic cardiomyoblast-derived H9c2 cells [15] have been 
widely used as a model system to study the protective mechanisms associated with 
flavonoids [6,7,13,14,16,17]. However, these studies have all been performed using 
mitotic H9c2 cardiomyoblasts, which although possessing similar morphological, 
electrophysiological, and biochemical properties to primary cardiomyocytes [18] are not 
fully differentiated cardiac cells. H9c2 cardiomyoblasts can be differentiated towards a 
more cardiomyocyte-like phenotype by culturing cells in reduced serum medium 
containing all-trans retinoic acid [19,20]. These conditions promote the expression of 
cardiac specific L-type Ca2+ channels and troponin 1 and induce the appearance of 
cardiomyocyte-like ultra-structural features [19,20].  
    The primary aim of this study was to investigate the cardioprotective actions of quercetin 
and two of its major in vivo metabolites (quercetin 3-glucuronide and 3’-O-methyl 
quercetin) using differentiated H9c2 cells. The ability of quercetin and its metabolites to 
elicit cell survival were assessed by monitoring oxidative stress-induced cell death. The 
potential role of MAPK (e.g. ERK1/2, p38 MAPK and JNK) and PKB signalling pathways in 
mediating the protective effects of quercetin were also explored. The main findings of the 
study indicate that quercetin protects differentiated H9c2 cardiac cells from oxidative stress 
induced death possibly via the inactivation of MAPK and PKB signalling.            
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Materials and Methods 
 
Materials 
Quercetin, quercetin 3-glucuronide, and all-trans retinoic acid were purchased from 
Sigma-Aldrich l Co. Ltd. (Poole, Dorset, UK). 3’-O-methyl quercetin was obtained from 
Extrasynthese (France). LY 294002, PD 98059, SB 203580, SP 600 125 and wortmannin 
were obtained from Tocris Bioscience (Bristol, UK). Dulbecco’s modified Eagle’s Medium 
(DMEM), foetal bovine serum (FBS), trypsin (10×), L-glutamine (200 mM), penicillin 
(10,000 U/ml)/streptomycin (10,000 g/ml) were purchased from Lonza Group Ltd. 
Antibodies were obtained from the following suppliers: monoclonal phospho-specific 
ERK1/2 (Thr202/Tyr204) from Sigma-Aldrich; polyclonal phospho-specific PKB (Ser473), 
polyclonal total unphosphorylated PKB, monoclonal total unphosphorylated ERK1/2, 
polyclonal total unphosphorylated JNK, polyclonal total unphosphorylated p38 MAPK, 
monoclonal phospho-specific p38 MAPK, and polyclonal cleaved active caspase 3 were 
from New England Biolabs (UK) Ltd;  monoclonal phospho-specific JNK was from Santa 
Cruz Biotechnology Inc and cardiac specific troponin 1 from Abcam (Cambridge, UK). All 
other chemicals were of analytical grade. Stock concentrations of quercetin (100 mM) 
were dissolved in DMSO, which was present in all treatments including the control at a 
final concentration of 0.1% (v/v). 
 
Cell culture 
Rat embryonic cardiomyoblast-derived H9c2 cells were obtained from the European 
Collection of Animal Cell Cultures (Porton Down, Salisbury, UK). Undifferentiated cells were 
cultured in Dulbecco's modified Eagle’s Medium (DMEM) supplemented with 2 mM L-
glutamine, 10% (v/v) FBS, penicillin (100 U/ml) and streptomycin (100 g/ml). Cells 
were maintained in a humidified incubator (95% air/5% CO2 at 37°C) until 70-80% 
confluent, detached using trypsin (0.05% w/v)/EDTA (0.02% w/v) and sub-cultured (1:5 
split ratio. Differentiation of H9c2 cells was induced by culturing the cells for 7 days in 
DMEM supplemented with 1% FBS (v/v) and 10 nM all-trans retinoic acid [19,20]. The 
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medium was replaced every two days and differentiation into a more cardiomyocyte-like 
phenotype confirmed by monitoring the expression of cardiac troponin 1 by 
immunocytochemistry and Western blotting, as described previously [20].    
 
Immunocytochemistry 
The differentiation of H9c2 cells was visually analysed by monitoring the expression of 
cardiac specific troponin 1 via immunocytochemistry. H9c2 cells were seeded in 8-well 
chamber slides (BD Falcon™ CultureSlide) at a density of 1.5 ×104 cells/well and 
cultured for 24 h, after which the medium was removed, replaced with differentiation 
medium and incubated for a further 7 days, changing the medium every two days. The 
medium was then removed and adherent differentiated cells washed with phosphate 
buffered saline (PBS) pre-warmed to 37°C . Cells were fixed with 3.7% (w/v) 
paraformaldehyde (Sigma-Aldrich, UK) in PBS, for 15 min at room temperature without 
agitation and then washed gently three times for 5 min with PBS. After fixation, 
permeabilisation was performed by incubating cells for 15 min at room temperature with 
0.1% (v/v) Triton X-100 in PBS followed by washing three times for 5 min with PBS. 
Cells were then incubated for 1 h at room temperature with 3% (w/v) bovine serum 
albumin (BSA) in PBS to prevent non-specific antibody binding. Cells were then 
incubated overnight at 4oC in a humidified chamber with anti-cardiac specific troponin 1 
antibody (1:1000) in 3% (w/v) BSA in PBS. Unbound primary antibody was then 
removed and the wells washed three times for 5 min with PBS. Cells were then 
incubated for 2 h at 37oC in a humidified chamber with fluorescein isothiocyanate (FITC)-
conjugated anti-mouse immunoglobulin G (Abcam), diluted 1:1000) in 3% (w/v) BSA in 
PBS. The chamber slides was subsequently washed three times for 5 min with PBS, air 
dried and mounted with Vectashield medium (Vector Laboratories Ltd, Peterborough, 
UK) containing DAPI counterstain for nuclei visualisation. Finally slides were sealed using 
clear, colourless nail varnish and stained cells visualised using an Olympus DP71 
epifluorescence microscope system equipped with an argon/krypton laser (FITC: 
E495/E278; DAPI: E360/E460).  
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Oxidative stress-induced cell death  
Differentiated H9c2 cells in fully supplemented DMEM were treated for 2 h with 600 M 
H2O2. To assess the effects of quercetin, cells were treated for 24 h in fully 
supplemented DMEM prior to 2 h H2O2 exposure. Where appropriate, cells were also 
treated for 30 min with the following protein kinase inhibitors; PD 98059 (50 µM; 
MEK1/2 inhibitor), LY 294002 (30 µM; PI-3K inhibitor); wortmannin (100 nM; PI-3K 
inhibitor), SB 203580 (30 µM; p38 MAPK inhibitor) or SP 600125 (10 µM; JNK1/2 
inhibitor) before the addition of quercetin (24 h in the continued presence of the kinase 
inhibitors). Medium containing quercetin and inhibitors was removed and replaced with 
fresh fully supplemented DMEM prior to H2O2 treatment. In a separate set of 
experiments cells were treated for 24 h with the above protein kinase inhibitors prior to 
H2O2 treatment. 
 
MTT reduction assay 
Undifferentiated H9c2 cells were plated in 24-well flat bottomed plates (15,000 cells per 
well) and cultured for 24 h in fully supplemented DMEM. Cells were subsequently induced 
to differentiate for 7 days as described above. Cell viability was determined by measuring 
the metabolic reduction of MTT (3-(4-5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) to a coloured formazan product. Briefly, cells were incubated for 1 h in 0.5 mg/ml 
MTT (in the continued presence of H2O2 or hypoxia) after which the medium was removed 
and replaced with 200 l DMSO. The magnitude of the reduction reaction was determined 
by monitoring the absorbance of the solubilised formazan product at 570 nm. 
 
Lactate dehydrogenase assay 
H9c2 cells were plated in 96-well flat bottomed plates (5,000 cells per well) and cultured 
for 24 h in fully supplemented DMEM. Cells were subsequently induced to differentiate for 
7 days prior to experimentation. The activity of lactate dehydrogenase (LDH) released 
into the culture medium was detected colourimetrically using the CytoTox 96® Non-
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Radioactive Cytotoxicity assay (Promega, Southampton, UK). Assays were performed 
according to the manufacturer’s instructions and changes in absorbance monitored at 
490 nm. 
 
Western blot analysis of caspase 3 activity and protein kinase phosphorylation  
Analysis of caspase 3 activity and protein kinase phosphorylation was performed using 
differentiated H9c2 cells (7 days) cultured in 25 cm2 tissue culture flasks. Following 
experimentation, cell supernatants were removed and the cells washed twice with warm 
PBS (37°C) to remove serum proteins, after which 300 l of hot sodium dodecyl sulphate 
buffer (0.5% w/v SDS in Tris buffered saline: TBS; 20 mM Tris base, 150 mM NaCl) were 
added and the resultant cell lysate boiled for 5 min prior to storage at -20°C. Protein 
concentration was determined using Bio-Rad DC Protein assay (Bio-Rad laboratories, 
Hertfordshire, UK) with BSA as the standard. Protein samples (30 g) were separated by 
polyacrylamide gel electrophoresis in the presence of SDS (SDS-PAGE) in a  10% w/v 
polyacrylamide resolving gel, using a Bio-Rad Mini-Protean III system. Proteins were 
transferred to nitrocellulose membrane filters using a Bio-Rad Trans-Blot system (1 h at 
100 V in 25 mM Tris, 192 mM glycine and 20% (v/v/) MeOH). Following transfer, the 
membranes were washed with TBS and blocked for 1 h at room temperature in blocking 
buffer (5% w/v skimmed milk powder and 0.1% v/v Tween-20 in TBS). Blots were then 
incubated overnight at 4oC in blocking buffer with the following primary antibodies 
(1:1000 dilutions unless otherwise indicated): phospho-specific ERK1/2, phospho-
specific PKB (1:500), phospho-specific p38 MAPK, phospho-specific JNK or cleaved active 
caspase 3 (1: 500). The primary antibody was removed and the blot extensively washed 
three times for 5 min in TBS/Tween 20. Blots were then incubated for 1 h at room 
temperature with the appropriate secondary antibody (1:1000) coupled to horseradish 
peroxidase (DAKO Ltd, Cambridge, UK) in blocking buffer. Following removal of the 
secondary antibody, blots were extensively washed as above and developed using the 
Ultra Chemiluminescence Detection System (Cheshire Sciences Ltd, Chester, UK) and 
quantified by densitometry using Advanced Image Data Analysis Software (Fuji; version 
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3.52). The uniform transfer of proteins to the nitrocellulose membrane was routinely 
monitored by transiently staining the membranes with Ponceau S stain (Sigma Chemical 
Co.) prior to application of the primary antibody. In addition, replicate samples from 
each experiment were analysed on separate blots using primary antibodies that 
recognise total unphosphorylated ERK1/2, PKB, p38 MAPK and JNK (all 1:1000 dilution) 
in order to confirm the uniformity of protein loading. 
 
Determination of intracellular oxidative stress 
Oxidative stress was determined using 2′,7′-dichlorofluorescein diacetate (DCFDA), a 
reactive oxygen species (ROS) sensitive fluorescent probe (Abcam, Cambridge, UK).  
Analysis of ROS production was performed using H9c2 cells differentiated for 7 days in 
25 cm2 tissue culture flasks.  Following 100 µM quercetin treatment (24, 48 and 72 h) cells 
were detached using trypsin (0.05% w/v)/EDTA (0.02% w/v), centrifuged and the resulting 
pellet re-suspended in 500 µl PBS containing 5 µM DCFDA and incubated for 30 min at 
37°C. Following incubation, the cell suspension was transferred to FACS tubes (Fisher 
Scientific, Loughborough, UK) and DCFDA fluorescence (excitation 495 nm; emission 529 
nm) measured using a Gallios™ flow cytometer (Beckman Coulter). The flow cytometer 
was set to count 10,000 cells in each treatment, and positive fluorescence was gated in 
relation to the untreated control. Results are reported as the percentage of cells showing 
positive fluorescence.  
 
Data analysis 
Statistical significance was determined by ANOVA with a post hoc Dunnett’s test (P<0.05 
was considered statistically significant). All data are presented as means + S.E.M. The n in 
the text refers to the number of separate experiments. 
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Results 
3.1 Differentiation of H9c2 cells and quercetin cardiotoxicity 
Mitotic H9c2 cells derived from embryonic rat heart tissue [15] are increasingly used as 
an in vitro model for studies exploring cardioprotection since they display similar 
morphological, electrophysiological and biochemical properties to primary cardiac 
myocytes [18]. However, mitotic H9c2 cells can be differentiated into a more 
cardiomyocyte-like phenotype when cultured in DMEM supplemented with 1% FBS (v/v) 
and 10 nM all-trans retinoic acid [19,20]. In this study mitotic H9c2 cells were cultured in 
differentiation medium for 1, 3, 7 and 9 days. As shown in Figure 1 the expression of 
cardiac troponin 1 increased markedly after 7 days, confirming H9c2 cell differentiation into 
a more cardiomyocyte-like phenotype. Hence, H9c2 cells differentiated for 7 days were 
used throughout the study and initial experiments investigated whether quercetin induced 
cardiotoxicity.   
 
Differentiated H9c2 cells were exposed to quercetin for 24, 48 and 72 h, after which cell 
viability was assessed by monitoring MTT reduction and LDH release. As shown in Figure 2a 
and 2b, exposure to quercetin (1-100 M) for 24 h had no significant effect on cell viability. 
In contrast, increasing quercetin exposure time to 48 h resulted in the inhibition of MTT 
reduction at quercetin concentrations of 100 M and 30 M (Figure 2c) and increased LDH 
release at 100 M (Figure 2d). Increasing the exposure time to 72 h resulted in 
cardiotoxicity at 10 M quercetin, when assessed by the inhibition of MTT reduction (Figure 
2e). Similarly after 72 h exposure, increased LDH release was observed at 30  µM quercetin 
(30 M) when compared to 48 h exposure to the same concentration of flavonoid (Figure 
2f).  Overall, these observations indicate that quercetin-induces cardiotoxicity at a 
concentration (10 M) achievable in the plasma through dietary supplements or quercetin-
enriched foods [4]. Since MTT reduction and LDH release do not discriminate between 
apoptotic and necrotic forms of cell death, the effect of quercetin on caspase 3 activity (a 
marker of apoptotic cell death) was determined. As shown in Figure 3, exposure to 100 M 
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quercetin (48 h and 72 h) induced a significant increase in caspase 3 activity, suggesting 
that quercetin-induced apoptosis contributes to cardiotoxicity.  
  The cardiotoxicity of quercetin may be a consequence of its intracellular metabolism to a 
semiquinone and/or quinone, both of which function as pro-oxidants [21,22]. Hence we 
determined whether the cardiotoxic effect of quercetin was due to its pro-oxidant 
properties. Levels of ROS were measured using the fluorescent probe DCFDA. As shown in 
Figure 4, exposure to 100 M quercetin (48 h and 72 h) induced a significant increase in 
ROS, suggesting that quercetin-induced oxidative stress contributes to cardiotoxicity. 
   In order to understand the mechanism(s) of quercetin-induced cardiotoxicity more fully, 
the effect of quercetin on protein kinase cascades associated with cell survival and cell 
death e.g. ERK1/2, p38 MAPK, JNK and PKB was investigated. Modulation of protein kinase 
activity was assessed by Western blotting using phospho-specific antibodies that recognise 
phosphorylated motifs within activated ERK1/2 (pTEpY), p38 MAPK (pTGpY), JNK (pTPpY) 
and PKB (S473). As shown in Figure 5a, 100 M quercetin attenuated ERK1/2 
phosphorylation following 24 h exposure. Similarly, 100 M quercetin inhibited the level of 
phosphorylated PKB after 24 h exposure, whereas later time points (48 and 72 h) displayed 
significant increases in PKB phosphorylation (Figure 5b). Finally, the levels of 
phosphorylated p38 MAPK and JNK were both significantly increased following 72 h 
treatment with 100 M quercetin (Figure 5c and 5d).  
   We also investigated the cardiotoxicity of two major in vivo quercetin metabolites; 3’-O-
methyl quercetin and quercetin 3-glucuronide. As shown in Figure 6, exposure to 
quercetin 3-glucuronide for up 72 h had no significant on H9c2 cell viability, as judged 
by MTT reduction and LDH release. In contrast, 3’-O-methyl quercetin-induced 
cardiotoxicity was clearly evident at a concentration of 3 µM following 48 h and 72 h 
treatment, when assessed using MTT reduction (Figure 7). However, when monitoring LDH 
release, 3’-O-methyl quercetin-induced cardiotoxicity was only evident at a concentration of 
100 µM following 24 and 48 h exposure.  
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3.2 Effect of quercetin on oxidative stress-induced cell death  
As outlined in the Introduction, previous studies have used mitotic H9c2 cells to explore 
the cardioprotective mechanisms of flavonoids [6,7,13,14,16,17]. In this study we 
investigated the ability of quercetin and two of its major in vivo metabolites (quercetin 
3-glucuronide and 3’-O-methyl quercetin) to protect differentiated H9c2 cells from H2O2-
induced cell death. The effects of 24 h flavonoid pre-treatment on H2O2-induced cell 
damage were assessed by monitoring MTT reduction by cellular dehydrogenases and LDH 
activity released into the medium. As shown in Figure 8a, quercetin-induced a 
concentration-dependent attenuation of H2O2 (600 M; 2 h) induced inhibition of MTT 
reduction, with significant protection still evident at a concentration of 3 M. Similarly, 
quercetin at concentrations of 100 M and 30 M inhibited H2O2-induced release of LDH 
(Figure 8b). Next, the effects of two major in vivo quercetin metabolites (3’-O-methyl 
quercetin and quercetin 3-glucuronide) on H2O2-induced cell damage were investigated. 
As shown in Figure 9, pre-treatment of differentiated H9c2 cells for 24 h with quercetin 
3-glucuronide had no significant effect on H2O2-induced inhibition of MTT reduction or LDH 
release. In contrast, 3’-O-methyl quercetin elicited statistically significant protection at 100 
µM. The partition co-efficient (LogP) values for quercetin 3-glucuronide (-0.49), quercetin 
(1.68) and  3’-O-methyl quercetin (1.96) indicate that the glucuronide conjugate is less 
lipophilic, which may explain the lack of effect (both cardiotoxicity and cardioprotection) 
of  quercetin 3-glucuronide observed in this study. 
   
3.3 Effect of quercetin on oxidative stress-induced protein kinase activation  
In order to understand the mechanism(s) of quercetin-induced protection against H2O2-
induced cell damage, the effect of quercetin on H2O2-induced protein kinase activation (e.g. 
ERK1/2, p38 MAPK, JNK and PKB) was investigated using western blotting. Previous studies 
have shown that reactive oxygen species, including H2O2, activate an array of intracellular 
signalling pathways that are associated with cell death and survival [23]. Indeed, studies 
have reported H2O2-induced activation of ERK1/2, p38 MAPK, JNK and PKB pathways in 
cardiomyocytes [24-26]. In this study, treatment of differentiated H9c2 cells with 600 µM 
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H2O2 for 2 h triggered the activation of ERK1/2, PKB, p38 MAPK and JNK (Figure 10). Pre-
treatment with 30 µM quercetin (24 h) significantly attenuated H2O2-induced activation of 
ERK1/2, PKB, p38 MAPK and JNK (Figure 10). These observations suggest that the 
protective actions of quercetin may involve the inactivation of signalling pathways involving 
ERK1/2, PKB, p38 MAPK and JNK. It should be noted that 24 h pre-treatment with 30 µM 
quercetin did not significantly attenuate the control levels of phosphorylated ERK1/2 and 
PKB (Figure 10). These data are surprising, since quercetin is a competitive inhibitor of the 
ATP-binding domain in MEK1 (an up-stream kinase associated with ERK1/2 activation) and 
PI-3K (a lipid kinase involved in PKB activation). However, as shown in Figure 11, 
increasing the concentration of quercetin to 100 µM (24 h treatment) significantly inhibited 
basal phosphorylation of ERK1/2 and PKB. For comparison 30 min pre-treatment with 
PD98059 (50 µM) and LY 294002 (30 µM), inhibitors of MEK1 and PI-3K respectively, 
attenuated basal levels of phosphorylated ERK1/2 and PKB (Figure 11). These data would 
seem to suggest that 30 µM quercetin-induced attenuation of H2O2-induced ERK1/2 and 
PKB signalling is independent of MEK1 and PI-3K inhibition. 
  Previous studies have shown that quercetin protects mitotic H9c2 cells against H2O2-
induced cell death via the activation of ERK1/ 2 and PI-3K/PKB signalling pathways [13]. In 
the current study, 24 h  treatment of differentiated H9c2 cells with PD 98059 (50 µM; 
MEK1/2 inhibitor), LY 294002 (30 µM; PI-3K inhibitor); wortmannin (100 nM; PI-3K 
inhibitor), SB 203580 (30 µM; p38 MAPK inhibitor) or SP 600125 (10 µM; JNK1/2 
inhibitor) had no significant effect on cell viability (Figure 12a) or quercetin mediated 
protection (Figure 12b). Similarly, these protein kinase inhibitors had no significant 
effect on H2O2-induced cell death (Figure 12c). Western blot analysis using phospho-
specific ERK1/2, p38 MAPK, JNK, and PKB antibodies confirmed inhibition of kinase 
activation by the above protein kinase inhibitors (data not shown) . 
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Discussion 
 
Quercetin-induced cardiotoxicity 
Initial experiments explored the potential cytotoxic effects of quercetin exposure using 
differentiated H9c2 cells. In agreement with previous studies, albeit using mitotic H9c2 
cells [13], 24 h exposure to quercetin (up to 100 µM) had no significant effect on the 
viability of differentiated H9c2 cells. However, quercetin-induced cardiotoxicity was 
evident following 48 h exposure with significant inhibition of MTT reduction at quercetin 
concentrations of 100 M and 30 M and increased LDH release at 100 M. At 72 h 
cardiotoxicity was evident at 10 M quercetin when assessed by the inhibition of MTT 
reduction. The difference in sensitivity between MTT and LDH assays is in agreement with 
previous studies which have reported the MTT assay as being more sensitive in detecting 
cytotoxic events [27]. To our knowledge this is the first report describing cardiotoxic effects 
of quercetin following prolonged (>48 h) exposure and importantly occurring at 
concentrations (10 µM) achievable in the plasma through ingestion of dietary supplements 
or quercetin-enriched foods  [4]. These cytotoxic effects are consistent with previous 
studies showing that quercetin triggers or enhances drug-induced apoptosis in leukaemia 
cell lines [28], human prostate cancer cells [29] and mouse cortical neurons [30]. The 
cytotoxic effects of quercetin may relate to its intracellular metabolism to pro-oxidative 
metabolites [21,22]. In this study prolonged quercetin treatment of H9c2 cells (>48 h) 
resulted in the generation of ROS, which supports a role for pro-oxidative damage in the 
mechanism of quercetin-induced cardiotoxicity. 
   We also explored the potential cardiotoxicity effects of two major in vivo quercetin 
metabolites; 3’-O-methyl quercetin and quercetin 3-glucuronide. The observation that 
quercetin 3-glucuronide had no significant effect on the viability of differentiated H9c2 
cells following 72 h exposure at concentrations up to 100 µM is in agreement with a 
previous study, which reported no damage to primary neuronal cells following exposure 
to quercetin 7-glucuronide for 6 h [30]. The lack of effect of quercetin 3-glucuronide may 
reflect the reduced lipophilicity of glucuronide conjugates. In marked contrast, the 
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metabolite 3’-O-methyl quercetin triggered cardiotoxicity following 48 and 72 h exposure 
with significant inhibition of MTT reduction evident at 3 µM.  These data are in agreement 
with Angeloni et al. [13] who reported no decrease in the ability of mitotic H9c2 cells to 
reduce MTT following 24 h treatment with 3’-O-methyl quercetin (1-30 µM). However, as 
seen in this study cellular toxicity to 3’-O-methyl quercetin is evident in differentiated H9c2 
cells following prolonged (> 48h) exposure. In contrast, cellular toxicity of 3’-O-methyl 
quercetin has been observed in primary neuronal cells following 6 h exposure [30]. When 
monitoring the effect of 3’-O-methyl quercetin and using LDH release as a marker of cell 
viability, cardiotoxicity was only evident at 24 and 48 h at a concentration of 100 µM.  It is 
not clear why there is no release of LDH following 72 h treatment with 3’-O-methyl 
quercetin despite the significant inhibition of MTT reduction at the same time point. It may 
be that 3’-O-methyl quercetin disrupts mitochondrial function without triggering necrotic 
cell death which is detected when monitoring LDH release. Similar to quercetin, the 
cytotoxic effects of 3’-O-methyl quercetin may also relate to its metabolism to pro-oxidative 
metabolites. Alternative assays for cell viability/cytoxicity, such as the neutral red assay 
which is based on the incorporation of the dye into lysosomes [31] or caspase-3 detection 
to assess apoptosis, may provide further clues as to the possible mechanism(s) of 3’-O-
methyl quercetin-induced cardiotoxicity. 
    In neuronal cells, quercetin-induced cell death involves the inhibition of cell survival 
signalling pathways (PKB and ERK1/2) and activation of caspase-3 [30]. In this study 
quercetin (100 µM) also triggered the activation of caspase-3 following 48 h and 72 h 
exposure, suggesting quercetin-induced cardiotoxicity involves apoptotic cell death. In 
order to understand more clearly the mechanism(s) of quercetin-induced cardiotoxicity the 
effect of prolonged quercetin exposure on protein kinase cascades associated with cell 
survival (ERK1/2 and PKB) and cell death (p38 MAPK and JNK) was investigated. In view of 
their respective roles in cell death and cell survival, it would be predicted that quercetin-
induced cardiotoxicity may involve attenuation of ERK1/2 and PKB signalling and/or 
activation of p38 MAPK and JNK. Since the molecular actions of quercetin include inhibition 
of the protein kinase MEK1 and the lipid kinase PI-3K, two critical up-stream kinases 
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involved in the activation of pro-survival ERK1/2 and PKB signalling cascades, respectively 
[32,33], pre-treatment of H9c2 cells with quercetin would be expected to attenuate levels 
of phosphorylated ERK1/2 and PKB. Indeed, quercetin attenuates MEK1 activity more 
effectively than the widely used MEK1 inhibitor PD98059 [34]. In this current study 
treatment with 100 µM quercetin for 24 h attenuated ERK1/2 phosphorylation. The effect of 
prolonged quercetin (100 µM) exposure on PKB phosphorylation revealed a biphasic 
response with inhibition observed following 24 h treatment, whereas later time points 
displayed increases in PKB phosphorylation. Previous studies have revealed conflicting data 
regarding the effects of quercetin on ERK1/2 and PKB signalling. For example, 24 h 
treatment with quercetin (30 µM) activates ERK1/2 and PKB in mitotic H9c2 cells [13]. 
Activation of ERK1/2 by quercetin has also been observed in macrophages (>50 µM for 40 
min; [35]) and pancreatic β cells (20 µM for 1 h; [36]). Finally quercetin (10 µM for 60 
min) induces increases in ERK1/2, JNK, p38 MAPK and PKB phosphorylation in HepG2 cells 
[8]. In contrast, quercetin inhibits ERK1/2 and PKB phosphorylation in neuronal cells (30 
µM up to 6 h; [30] and the anti-proliferative effect of quercetin on cancer cells is via PKB 
inhibition [37]. In this study, using differentiated H9c2 cells, 24 h exposure to quercetin (30 
µM) had no significant effect on the basal levels of phosphorylated (active) ERK1/2, p38 
MAPK, JNK or PKB. This presumably reflects the cellular metabolism of quercetin which is 
undetectable in mitotic H9c2 cells after 24 h exposure to 30 µM having peaked at 1 h [13]. 
In contrast, 24 h exposure to 100 µM quercetin significantly reduced basal levels of 
phosphorylated ERK1/2 and PKB. These data are comparable to results obtained using 
selective up-stream inhibitors of these protein kinases, namely PD98059 (MEK1 inhibitor) 
and LY 294002 (PI-3K inhibitor).   
    In this study prolonged treatment with quercetin (100 µM for 72 h) resulted in significant 
increases in the levels of phosphorylated p38 MAPK and JNK in differentiated H9c2 cells. 
Given the pro-apoptotic role of these kinases it is conceivable that their activation 
contributes to quercetin-induced cardiotoxicity. Although it is interesting to note that 
quercetin-induced neuronal damage appears to be independent of JNK [28]. Although it is 
not clear how quercetin induces an increase in JNK and p38 MAPK phosphorylation in 
17 
 
differentiated H9c2 cells, a recent study has revealed that quercetin (100 µM; 6 h) 
stimulates TAK1 and MKK3/6, two upstream kinases associated with p38 MAPK activation, 
in macrophages [38]. Further experiments are clearly needed to explore the connection 
between quercetin-induced activation of p38 MAPK/JNK and cell death, possibly through the 
use of selective pharmacological inhibitors of these kinases, although prolonged (72 h) 
treatment with such inhibitors may also induce cell death. Thus, quercetin-induced 
cardiotoxicity potentially involves the modulation of multiple protein kinase cascades 
associated with cell survival (ERK1/2 and PKB) and cell death (p38 MAPK and JNK). 
Although beyond the scope of the present study, future experiments will explore in more 
detail the concentration and time dependent effects of quercetin on these kinases and their 
upstream activators.  
 
Quercetin-induced cardioprotection 
In this study, we investigated the ability of quercetin and two of its major in vivo 
metabolites (quercetin 3-glucuronide and 3’-O-methyl quercetin) to protect differentiated 
H9c2 cells from H2O2-induced cell death. The data presented indicate that 24 h exposure to 
quercetin induced a concentration-dependent attenuation of H2O2 induced inhibition of MTT 
reduction, with significant protection still evident at a concentration of 3 M. At 
concentrations of 100 µM and 30 µM, quercetin  also induced protection when monitoring 
H2O2 induced LDH release. These observations are comparable to previous reports 
indicating that MTT assays are more sensitive for detecting cytotoxic insults when 
compared to LDH release assays [27].  Whilst comparable to previous studies reporting 
quercetin-induced cardioprotection using mitotic H9c2 cells, ours is the first study to report 
protection using differentiated H9c2 cells. A notable feature of the data presented in this 
study concerns the temporal nature of quercetin’s cardioprotective versus cardiotoxic 
effects. Treatment of H9c2 cells for 24 h with 10, 30 or 100 µM quercetin induces 
cardioprotection against H2O2 induced inhibition of MTT reduction (with no observable 
toxicity) whereas 72 h exposure to 10, 30 or 100 µM quercetin results in cardiotoxicity. 
The switch from a cardioprotective to cardiotoxic action may reflect a switch from anti-
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oxidant to pro-oxidant effects due to the accumulation of oxidative metabolites and/or a 
temporal modulation of multiple kinase pathways associated with cell death and survival.  
   Previous studies have shown that 3’-O-methyl quercetin (up to 30 µM) protects dermal 
fibroblasts against H2O2-induced cell damage, whereas quercetin 7-O–β-D-glucuronide had 
no protective effects [21]. Similar results were obtained in the current work, although the 
protective effects of 3’-O-methyl quercetin were only observed at a concentration of 100 
µM. The difference between the two quercetin metabolites may reflect their uptake into 
differentiated H9c2 cells. However, Angeloni et al. [13] reported that 3’-O-methyl quercetin 
did not protect mitotic H9c2 cells against oxidative damage.   
 
Mechanisms of quercetin-induced cardioprotection 
A previous report has shown that quercetin protects mitotic H9c2 cells against H2O2-induced 
cell death via the activation of ERK1/ 2 and PI-3K/PKB signalling pathways [13]. These data 
were based on the observation that pre-treatment of cells with PD98059 (MEK1 inhibitor) 
and LY 294002 (PI-3K inhibitor) attenuated quercetin-induced protection [13]. In this study 
treatment of cells with PD98059 (50 µM) and LY 294002 (30 µM) had no significant effect 
on 30 µM quercetin-induced protection. Similarly, inhibitors of p38 MAPK (SB203580; 30 
µM) and JNK (SP 600125; 10 µM) also had no effect on quercetin-induced protection. The 
apparent discrepancy between this study and Angeloni et al. [13] may reflect the use of 
mitotic versus differentiated H9c2 cells. However, it is important to note that in this study 
24 h quercetin (30 µM) pre-treatment did not activate PKB, ERK1/2, p38 MAPK or JNK and 
hence inhibitors of these kinases would not be expected to reverse the protective effect of 
quercetin.  
   The mechanism(s) of quercetin-induced protection against H2O2-induced cell damage 
may involve modulation of H2O2-induced protein kinase activation e.g. ERK1/2, PKB, p38 
MAPK, and JNK, since these signalling pathways are associated with redox-mediated cell 
death and survival [39]. However, in the current study, inhibitors of these kinases had no 
significant effect on H2O2-induced cell death. Previous studies have shown H2O2-induced 
activation of ERK1/2, p38 MAPK, JNK and PKB pathways in cardiomyocytes [24-26]. We 
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also observed significant activation of these kinase cascades by H2O2 (600 µM; 2 h) in 
differentiated H9c2 cells. Previous studies using mitotic H9c2 cells have shown that H2O2 
(150 µM; 1 h) attenuated PKB phosphorylation, whereas levels of phosphorylated ERK1/2 
were not modulated [13]. The disparity between the results obtained in this study and 
those of Angenloni et al. [13] may again be a consequence of the use of mitotic versus 
differentiated cells or concentration/exposure time to H2O2. The data presented in our study 
also reveals that pre-treatment of differentiated H9c2 cells with 30 µM quercetin attenuated 
H2O2-induced activation of ERK1/2, p38 MAPK, JNK and PKB. Previous studies have shown 
that H2O2 triggers apoptosis in H9c2 cells via activation of the mitochondria-dependent or 
intrinsic apoptotic pathway [14].  Interestingly, the flavonol isorhamnetin attenuated H2O2-
induced activation of mitochondrial-dependent apoptosis in H9c2 cells via ERK inactivation 
[14]. These observations are in agreement with the data obtained in the current study, 
suggesting that quercetin protects against H2O2-induced oxidative cell death via ERK1/2 
inactivation.  The attenuation of H2O2-induced p38 MAPK, JNK and PKB activation by 
quercetin is comparable to previous studies, which have reported quercetin inhibiting 
lipoteichoic acid (constituent of the cell wall of gram-positive bacteria) induced ERK1/2, 
JNK, p38 MAPK and  PKB activation in mitotic H9c2 cells [6]. Similarly, quercetin inhibited 
LPS-induced JNK and p38 MAPK activation in H9c2 cells [7]. Overall these observations 
indicate that quercetin is capable of attenuating protein kinase activation (ERK1/2, JNK, 
p38 MAPK and PKB) triggered via a range of different mediators (H2O2, lipoteichoic acid and 
LPS) in H9c2 cells. The inhibition of ERK1/2 and PKB may relate to the actions of quercetin 
as an inhibitor of MEK1 and PI-3K, although the observation that basal levels of ERK1/2 
and PKB phosphorylation are not inhibited by 24 h treatment with 30 µM flavonoid suggests 
otherwise. Hence, although the attenuation of H2O2-induced cell death by quercetin may be 
via ERK1/2 and PKB inhibition, these data suggest it is independent of MEK1 and PI-3K 
inhibition.  The attenuation of p38 MAPK and JNK signalling presumably reflects the 
inhibition of up-stream components of these two protein kinases. The potential mechanisms 
of how quercetin may modulate JNK and p38 MAPK signalling are discussed in detail by 
Spencer [40]. However, it is important to note that quercetin is known to inhibit a 
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multitude of other protein kinases that include CK2, AMPK, RSK2, S6K1, IKK, Hck and 16 
cell-cycle related kinases [4,41,42]. Although this study has shown that quercetin 
attenuates H2O2-induced PKB, ERK1/2, p38 MAPK and JNK activation and promotes cell 
survival, inhibitors of these kinases had no significant effect on H2O2-induced cell death. 
The discrepancy between these observations suggests that the protective effect of 
quercetin may be a consequence of the simultaneous inhibition of multiple kinase pathways 
as opposed to the lack of protection observed with inhibitors of individual kinase pathways.   
   It is important to note that quercetin in foods is glycosylated and, as such, plasma 
levels of the aglycone are very low or undetectable [4]. However, following ingestion, 
quercetin glycosides are rapidly hydrolysed in the gut to quercetin aglycone, which is 
subsequently metabolized into glucuronidated, sulphated or methylated derivatives via 
phase II conjugation reactions. It has also been suggested that many of the major 
metabolites of quercetin exhibit weaker in vitro effects than the parent compound [43]. 
The data presented is this study confirms this view, since quercetin 3-glucuronide did not 
elicit cardioprotection, whereas 3’-O-methyl quercetin was only effective at 100 µM. 
Furthermore, recent studies have suggested that circulating quercetin glucuronides in 
the plasma function as quercetin carriers, which when taken up by cells are de-
conjugated into the more active aglycone [44]. Hence in this study it is notable that 
quercetin 3-glucuronide was unable to produce either cardiotoxic or cardioprotective 
effects,  suggesting that this metabolite may not be de-conjugated in H9c2 cells.  
   In conclusion, this study has shown for the first time that 24 h treatment with quercetin 
induces cardioprotection against oxidative stress triggered cell death in differentiated H9c2 
cells, a cell-based model system that displays a more robust cardiomyocyte-like 
phenotype. In contrast, the in vivo metabolite quercetin 3-glucuronide displayed no 
protective effects against H2O2-induced cell damage. Although quercetin attenuated H2O2-
induced activation of ERK1/2, PKB, p38 MAPK and JNK, inhibitors of these kinases had no 
significant effect on quercetin-induced protection or H2O2-induce cell death. Prolonged 
exposure to quercetin (72 h) triggered cardiotoxicity which appears to involve apoptotic cell 
death and modulation of cell survival (PKB) and cell death (p38 MAPK and JNK) signalling 
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pathways. Cardiotoxicity was also observed with 3’-O-methyl quercetin but not quercetin 
3-glucuronide. Clearly further studies are required to explore the complex interplay 
between the numerous signalling pathways that are modulated by quercetin and thus 
may contribute to the observed cardioprotective and cardiotoxic effects of this important 
flavonoid.       
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Figure Legends 
 
Figure 1. Expression of cardiac troponin 1 during differentiation of H9c2 cells. Levels of 
cardiac troponin 1 were monitored following 1, 3, 7 and 9 days cell culture in 1% FBS 
(v/v) and 10 nM all-trans retinoic acid. (a) Immunocytochemistry by fluorescence 
microscopy was performed using cardiac troponin 1 specific antibody (green) and DAPI 
counterstain for nuclei visualisation (blue). Images presented are from one experiment 
and representative of three. (b) Levels of cardiac troponin 1 assessed by western blot. 
Data are expressed as the percentage of control undifferentiated cells (=100%) and 
represent the mean  SEM of three independent experiments. *P0.05 versus control 
response. 
 
Figure 2. Effect of quercetin on the viability of differentiated H9c2 cells monitored by 
MTT reduction and LDH release.  Differentiated H9c2 cells (7 day) were exposed to the 
indicated concentrations of quercetin for 24, 48 and 72 h. Following quercetin exposure 
cell viability was assessed by measuring (a, c, and e) metabolic reduction of MTT by 
mitochondrial dehydrogenases and (b, d and f) the release of LDH. Data are expressed 
as the percentage of control cells (=100%) and represent the mean  SEM of five 
independent experiments each performed in quadruplicate (MTT) or sextuplicate (LDH). 
*P0.05 versus control response. 
 
Figure 3. Effect of quercetin on caspase 3 activation. Differentiated H9c2 cells (7 day) 
were exposed to 100 M quercetin for (a) 24 h, (b) 48 h and (c) 72 h. Following 
quercetin exposure caspase 3 activation was assessed via Western blotting using anti-
active caspase 3 antibody. Data are expressed as the percentage of control cells (72 h 
=100%) and represent the mean  SEM of three independent experiments. *P0.05 
versus untreated control cells. 
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Figure 4. Effect of quercetin on reactive oxygen species production. Differentiated H9c2 
cells (7 day) were exposed to 100 M quercetin for (a) 24 h, (b) 48 h and (c) 72 h. 
Following quercetin exposure, ROS production was assessed via flow cytometry using the 
fluorescent probe DCFDA. Data are expressed as the percentage of fluorescent positive 
cells (10,000 sampled) in each condition  and represent the mean  SEM of three 
independent experiments. *P0.05, **P0.01 versus untreated control cells.  
 
Figure 5. Effect of prolonged quercetin exposure on protein kinase activation. 
Differentiated H9c2 cells (7 day) were exposed to 100 M quercetin for (a) 24 h, (b) 48 
h and (c) 72 h. Following quercetin exposure cell lysates were analysed by Western 
blotting for activation of (a) ERK1/2, (b) PKB, (c) p38 MAPK and (d) JNK using phospho-
specific antibodies. Samples were subsequently analysed on separate blots using 
antibodies that recognise total ERK1/2, PKB, p38 MAPK and JNK.  Time-matched control 
experiments (24, 48 and 72 h in the absence of quercetin) revealed no significant 
change in activated ERK1/2, PKB, p38 MAPK or JNK (data not shown). Data are 
expressed as the percentage of control cells (72 h =100%) and represent the mean  
SEM of three or four independent experiments. *P0.05 versus untreated control cells. 
 
Figure 6. Effect of quercetin 3-glucuronide on the viability of differentiated H9c2 cells 
monitored by MTT reduction and LDH release.  Differentiated H9c2 cells (7 day) were 
exposed to the indicated concentrations of quercetin 3-glucuronide (Q3G) for 24, 48 and 
72 h. Following quercetin 3-glucuronide exposure cell viability was assessed by 
measuring (a, c, and e) metabolic reduction of MTT by mitochondrial dehydrogenases 
and (b, d and f) the release of LDH. Data are expressed as the percentage of control 
cells (=100%) and represent the mean  SEM of six independent experiments each 
performed in quadruplicate (MTT) or sextuplicate (LDH).  
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Figure 7. Effect of 3’-O-methyl quercetin on the viability of differentiated H9c2 cells 
monitored by MTT reduction and LDH release.  Differentiated H9c2 cells (7 day) were 
exposed to the indicated concentrations of 3’-O-methyl quercetin (Q3M for 24, 48 and 72 
h. Following 3’-O-methyl quercetin exposure cell viability was assessed by measuring (a, 
c, and e) metabolic reduction of MTT by mitochondrial dehydrogenases and (b, d and f) 
the release of LDH. Data are expressed as the percentage of control cells (=100%) and 
represent the mean  SEM of six independent experiments each performed in 
quadruplicate (MTT) or sextuplicate (LDH). *P0.05, **P0.01, ***P0.005 versus 
control response. 
 
Figure 8. Effect of quercetin on H2O2-induced cell death. Differentiated H9c2 cells (7 day) 
were exposed to the indicated concentrations of quercetin for 24 h prior to 2 h exposure 
to 600 M H2O2 in the continued presence of quercetin. Cell viability was assessed by 
measuring (a) metabolic reduction of MTT and (b) LDH released into the culture medium. 
Data are expressed as the percentage of control cells (=100%) and represent the mean 
 SEM of six independent experiments each performed in (a) quadruplicate and (b) 
sextuplicate. *P0.05 versus H2O2 alone. 
 
Figure 9. Effect of quercetin 3-glucuronide and 3’-O-methyl quercetin on H2O2-induced 
cell death. Differentiated H9c2 cells (7 day) were exposed to the indicated 
concentrations of quercetin 3-glucuronide (Q3G) or 3’-O-methyl quercetin (Q3M) for 24 h 
prior to 2 h exposure to 600 M H2O2 in the continued presence of quercetin 3-
glucuronide or 3’-O-methyl quercetin. Cell viability was assessed by measuring (a and c) 
metabolic reduction of MTT and (b and d) LDH released into the culture medium. Data 
are expressed as the percentage of control cells (=100%) and represent the mean  SEM 
of five independent experiments each performed in quadruplicate (MTT) and sextuplicate 
(LDH). *P0.05 versus H2O2 alone. 
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Figure 10. Effect of quercetin on H2O2-induced protein kinase activation. Differentiated 
H9c2 cells (7 day) were exposed to 30 M quercetin for 24 h prior to 2 h exposure to 
600 M H2O2 in the continued presence of quercetin. Cell lysates were analysed by 
Western blotting for activation of (a) ERK1/2, (b) PKB, (c) p38 MAPK and (d) JNK using 
phospho-specific antibodies. Samples were subsequently analysed on separate blots 
using antibodies that recognise total ERK1/2, PKB, p38 MAPK and JNK.  Data are 
expressed as the percentage of control cells (=100%) and represent the mean  SEM of 
three independent experiments. *P0.05, a versus control cells and b versus H2O2 
treated cells. 
 
Figure 11. Effect of quercetin on ERK1/2 and PKB phosphorylation. Differentiated H9c2 
cells (7 day) were exposed to quercetin (100 µM and 30 M) for 24 h or PD 98059 (50 
µM) and LY294002 (30 µM) for 30 min. Cell lysates were then analysed by Western 
blotting for phosphorylated (a) ERK1/2 and (b) PKB, using phospho-specific antibodies. 
Samples were also analysed on separate blots using antibodies that recognise total 
ERK1/2 and PKB.  Data are expressed as the percentage of control cells (=100%) and 
represent the mean  SEM of three independent experiments. *P0.05 versus control 
response.  
 
Figure 12. Effect of protein kinase inhibitors on quercetin-induced cardioprotection. (a) 
Differentiated H9c2 cells were exposed to PD 98059 (50 µM; MEK1/2 inhibitor), 
wortmannin (100 nM; PI-3K inhibitor), LY 294002 (30 µM; PI-3K inhibitor); SB 203580 
(30 µM; p38 MAPK inhibitor) or SP 600125 (10 µM; JNK1/2 inhibitor) for 24 h. (b) 
Differentiated H9c2 cells were pre-treated for 30 min with the protein kinase inhibitors 
prior to 24 h quercetin (30 µM) followed by 2 h exposure to 600 M H2O2. (c) 
Differentiated H9c2 cells were pre-treated with protein kinase inhibitors for 24 h prior to 
2 h exposure to 600 M H2O2. 
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